$534 million! Genentech and Microbiotica collaborate to develop new drugs for inflammatory bowel disease!
June 7, 2018 Source: CPhI Pharma Online Author: Knowing and Doing
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Inflammatory bowel disease drug
On June 6, 2018, Roche's Genentech and Microbiotica established a long-term strategic partnership. The two sides will jointly develop and commercialize the biomarkers and targets for the treatment of inflammatory bowel disease in clinical research. With new drugs, gut microbes are gaining more and more attention and are seen as a new breakthrough in the treatment of many diseases.
Gut microbiota
The gut microbiota is an extremely complex group whose balance between species and quantity in the human body is closely related to the health of the individual. It is considered to be the "second genome" of human organs or humans due to the important role of the gut microbiota. . The function of the intestinal microbiota includes: maintaining the normal structure and physiological functions of the intestinal tract; antagonizing the colonization, infection and stimulation of pathogenic microorganisms; affecting the physiological functions of the body such as metabolism, cognitive function, hematopoiesis, inflammation and immunity. In recent years, more and more research has focused on the gut microbiota, and it is expected to be inspired by the development of innovative therapies from gut microbes.
Genentech and Microbiotica
On June 6, 2018, Genentech and Microbiotica, a leader company based on microbial research and development of innovative therapies, established a long-term strategic partnership. The cooperation between the two parties is mainly inflammatory bowel disease associated with intestinal microbes ( Treatment of Inflammatory Bowel Disease, IBD). IBD is a special chronic intestinal inflammatory disease, mainly including Crohn's disease (CD) and ulcerative colitis (UC), which have significant differences in intestinal microbial abundance.
According to the relevant protocol, MicroTecha will assist Genentech in identifying biomarkers that respond to drugs, discover new IBD drug targets, and correlate with gut microbes with Genentech's precise metagenomic platform. New treatments; Microbiotica will receive a total of $534 million including initial funding and milestones.
Studies in recent years have shown that intestinal microbes not only affect the systemic immune system, but also affect the efficacy of immunotherapy. For example, the use of antibiotics during the treatment of immunological checkpoint inhibitors can reduce the efficacy. The fecal transplantation of some patients is expected to improve the efficacy of immunotherapy. Therefore, intestinal microbes are expected to become a potential biomarker for predicting the efficacy of immunotherapy.
In addition, once the intestinal microbiota is disordered, it may lead to a variety of diseases. If you can find "bad microbes" that cause intestinal diseases such as IBD, use special compounds to target and inhibit specific diseases associated with the disease. Groups, without affecting the beneficial flora, that is, targeting "bad microorganisms".
Microbiotica's platform provides world-leading microbial culture collection technology and associated genomic databases for extremely accurate identification of intestinal microbes in clinical research. Microbiotica's efficient industrial culture and gene sequencing provide microbial identification at the bacterial level for clinical research, and the phenotype of microorganisms is determined by comparative analysis of complex data by AI, as well as the humanized microbiome group that can evaluate microorganisms. The mouse model helps Genentech to develop better new drugs.
James Sabry
(Image courtesy of Endpoints)
"We believe that microbiomes represent a new paradigm in biomedical science that not only provides a better understanding of drug response, but can also be a new treatment." Genentech Vice President James Sabry said in a statement "We have chosen to work with Microbiotica because of its high level of research capabilities and hope to bring innovative treatment to IBD patients through joint efforts."
Intestinal microbes are not only closely related to intestinal diseases, but recent studies have also shown that intestinal microbes are also associated with diabetes, autoimmune hepatitis, arteriosclerosis, blood sugar and lipid levels, heart disease, and cancer. Although the mechanism of action of intestinal microbes on some diseases is still unclear, the importance of gut microbes to human health is unquestionable. More and more scholars regard gut microbes as a new medical research direction.
Reference source:
1.Genentech dives deeper into the microbiome, inking $534M deal with Microbiotica to develop IBD meds;
2. Microbiotica Enters into Microbiome Collaboration with Genentech.
Pharmaceutical Gelatin,Pharmaceutical Gelatin For Oil Soft,Pharmaceutical Grade Gelatin,High Bloom Pharmaceutical Gelatin
Hebei Haodong Biological Technology Co.,Ltd. , https://www.hdgelatin.com